Persistent Asthma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Persistent Asthma Market Outlook
Thelansis’s “Persistent Asthma Market
Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024
To 2034" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Persistent Asthma treatment modalities
options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan,
and China).
Persistent
Asthma Overview
Persistent
asthma is a chronic inflammatory airway disorder characterized by recurring
symptoms such as wheezing, breathlessness, chest tightness, and coughing, which
occur more than twice a week and often interfere with daily activities or
sleep. Unlike intermittent asthma, persistent forms involve sustained airway
hyperresponsiveness and inflammation, requiring long-term controller therapy to
prevent exacerbations and maintain lung function. The condition is typically
classified into mild, moderate, or severe categories based on symptom
frequency, lung function tests, and the intensity of treatment needed for
control. Pathophysiologically, persistent asthma involves complex immune
mechanisms—often driven by eosinophilic or neutrophilic inflammation—and structural
changes in the airway, including smooth muscle hypertrophy and mucus
hypersecretion. Management typically involves the daily use of inhaled
corticosteroids, often in combination with long-acting beta-agonists or other
adjunctive agents, such as leukotriene receptor antagonists or biologics
targeting IgE or interleukins, depending on the phenotype and severity.
Environmental control, adherence to therapy, and regular monitoring are
essential to reduce the risk of acute exacerbations, hospitalizations, and
long-term airway remodeling.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment